rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Matinas Biopharma Holdings, Inc.

MTNB · NYSE American

Health CareBiotechnologyNot moving yet

MTNB stood above a rising 150-day average in 2 of the last 52 weekly readings, and has been out of that trend for the last 50 weeks. It is 74.3% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 50
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
25 (-2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 2 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders25-2 on the quarter
New · exited2 · 5
Reported value$199K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 202671,040$43K+42,470+148.7%
BlackRock, Inc.added · filed 7 Aug 202650,262$31K+612+1.2%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202649,135$30K-16,035−24.6%
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 202640,110$25K00.0%
Holos Integrated Wealth LLCunchanged · filed 15 Jul 202632,480$20K00.0%
VANGUARD FIDUCIARY TRUST COreduced · filed 13 Aug 202617,316$11K-961−5.3%
SUSQUEHANNA INTERNATIONAL GROUP, LLPadded · filed 14 Aug 202616,093$9,849+1,765+12.3%
CITADEL ADVISORS LLCreduced · filed 14 Aug 202615,465$9,465-36,233−70.1%
STATE STREET CORPunchanged · filed 7 Aug 202615,322$9,37700.0%
Sargent Investment Group, LLCunchanged · filed 11 Aug 202612,720$7,78500.0%
30 Sep 2024 – 30 Jun 2026
172328Sep 24Mar 25Sep 25Dec 25Jun 26

Everyone who traded it

Adam K. Stern Company insider10% owner · last 10 Jul 202611 · 0
Sanitam Partners LLC Company insider10% owner · last 10 Jun 20260 · 0
An Evelyn D Company insiderDirector · last 30 Apr 20250 · 0
Edward Neugeboren Company insiderDirector · last 30 Apr 20250 · 0
Jerome D. Jabbour Company insiderPresident and CEO · last 30 Apr 20253 · 0
Keith Murphy Company insiderDirector · last 30 Apr 20250 · 0
Robin L. Smith Company insiderDirector · last 30 Apr 20250 · 0
Pembroke & Partners Llc Company insider10% owner · last 8 Apr 20250 · 0
Robert J. Eide Company insider10% owner · last 8 Apr 20250 · 0
Hui Liu Company insiderChief Technology Officer · last 15 Dec 20230 · 0
James J. Ferguson III Company insiderChief Medical Officer · last 15 Dec 20230 · 0
Keith A. Kucinski Company insiderChief Financial Officer · last 15 Dec 20232 · 0

Same industry

MRNA ModernaLeading+167%
IOVA Iovance BiotherapeuticsLeading+141%
ABCL AbCellera BiologicsLeading+57%
ENTX Entera BioLeading+52%
HALO Halozyme TherapeuticsLeading+48%
XERS Xeris Biopharma HoldingsLeading+47%
XNCR XencorLeading+41%
HELP Helus PharmaLeading+39%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-121%
Share count trendFY 2025 · to 26 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$4.0M

Analyst forecasts

No analyst forecasts yet.